Comparative Study of Sonazoid and SonoVue Contrast‐Enhanced Ultrasound Quantitative Analysis Parameters in Peripheral Lung Cancer Lesions
Journal of Clinical Ultrasound · 2025
DOI: 10.1002/jcu.24011 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Clinical Ultrasound, 2025. Verfasst von Guosheng Liang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ultrasound, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong Province, China. Hauptthemen laut MEDLINE: Contrast Media, Lung Neoplasms, Oxides, Ferric Compounds. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Guangzhou Municipal Science and Technology Bureau Basic Research Program - City-University Joint Project.
Abstract (Originalsprache)
Purpose
Lung cancer is a leading cause of death; however, its diagnosis needs to be improved. This study aimed to compare the performances of the contrast agents Sonazoid and SonoVue in quantitative analysis in the contrast‐enhanced ultrasound (CEUS) of peripheral lung cancer lesions (PLCLs).
Methods
This retrospective study included patients with PLCLs between January 2021 and January 2024. They were divided into the Sonazoid‐CEUS (50 patients) and SonoVue‐CEUS (53 patients) groups. In the CEUS video, lesions and adjacent normal lung tissues were selected as regions of interest to obtain time‐intensity curves. Seven CEUS indicators were used to compare the performances of the two contrast agents.
Results
The arrival times (ATs) were 13.1 ± 5.2 s and 11.5 ± 3.7 s for PLCLs ( p = 0.087), respectively, and 8.0 ± 4.1 s and 7.0 ± 4.2 s for adjacent lung tissues ( p = 0.197), respectively, in the Sonazoid and SonoVue groups. The peak intensity (PI) and area under the curve (AUC) of the lesions in the Sonazoid group were significantly lower than those in the SonoVue group (PI: 25.0 ± 11.5 vs. 35.8 ± 7.9, p < 0.001; AUC: 2365.2 ± 1708.2 vs. 4309.5 ± 1252.1, p < 0.001). The time to peak (TTP), mean transition time (MTT), and lesion–lung PI difference (ΔPI) in the Sonazoid group were significantly higher than those in the SonoVue group (TTP: 36.3 ± 13.8 s vs. 24.4 ± 8.7 s, p < 0.001; MTT: 119.6 ± 45.3 s vs. 80.6 ± 21.4 s, p < 0.001; ΔPI: 14.3 ± 10.9 vs. 8.4 ± 6.1, p < 0.01).
Conclusion
Sonazoid and SonoVue exhibited comparable quantitative performances in CEUS of PLCLs; the higher ΔPI of Sonazoid suggests it may enhance the contrast between lesions and adjacent tissues. The study's findings could help improve lung cancer diagnosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ultrasound, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong Province, China.
- The State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Disease, the First Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China.
ORCID-Profile: Guosheng Liang
Förderung
- Guangzhou Municipal Science and Technology Bureau Basic Research Program - City-University Joint Project
Zitieren
APA
Liang, G., Chen, W., Tang, J., Jiang, T., Zhang, Y., Zhang, S., Tang, Q., & He, L. (2025). Comparative Study of Sonazoid and SonoVue Contrast‐Enhanced Ultrasound Quantitative Analysis Parameters in Peripheral Lung Cancer Lesions. Journal of Clinical Ultrasound. https://doi.org/10.1002/jcu.24011
Vancouver
Liang G, Chen W, Tang J, Jiang T, Zhang Y, Zhang S, et al. Comparative Study of Sonazoid and SonoVue Contrast‐Enhanced Ultrasound Quantitative Analysis Parameters in Peripheral Lung Cancer Lesions. Journal of Clinical Ultrasound. 2025. doi:10.1002/jcu.24011
BibTeX
@article{Liang2025,
author = {Liang, Guosheng and Chen, Wuxi and Tang, Jiaxin and Jiang, Tingting and Zhang, Yuxin and Zhang, Shiyu and Tang, Qing and He, Liantu},
title = {Comparative Study of Sonazoid and SonoVue Contrast‐Enhanced Ultrasound Quantitative Analysis Parameters in Peripheral Lung Cancer Lesions},
journal = {Journal of Clinical Ultrasound},
year = {2025},
doi = {10.1002/jcu.24011}
}
EUVIMED